文献速递免疫规划

第二剂麻疹-腮腺炎-风疹-水痘疫苗(MMRV)与热性惊厥风险

Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions.
PubMed 文献 · Vaccine · 2022-02-26

基于德国GePaRD数据库的回顾性队列研究,纳入2004年1月1日至2015年10月31日出生、接种两剂MMRV、MMR+V或MMR的儿童。第二剂接种后30天内共观察到464例热性惊厥,调整后MMRV对比MMR+V的OR为1.25(95%CI 0.67-2.30),对比MMR的OR为1.04(0.82-1.32)。结论认为第二剂使用MMRV与MMR+V或MMR相比未增加热性惊厥风险,且不受年龄、性别、热性惊厥史或第一剂疫苗类型影响。

要点

  • 第二剂MMRV对比MMR+V的热性惊厥调整OR为1.25(95%CI 0.67-2.30),未达统计学显著。
  • 第二剂MMRV对比MMR的热性惊厥调整OR为1.04(95%CI 0.82-1.32),未达统计学显著。
  • 热性惊厥史是最重要的危险因素,OR为36.26(95%CI 29.30-44.89)。

核心结论

  • 第二剂接种MMRV与MMR+V或MMR相比,未发现热性惊厥风险增加,且不受年龄、性别、热性惊厥史或第一剂疫苗类型影响。

研究设计与样本

  • 回顾性队列研究,使用德国药物流行病学研究数据库(GePaRD)的理赔数据,纳入2004年1月1日至2015年10月31日出生、接种两剂MMRV、MMR+V或MMR的儿童,队列共528,639名儿童,中位年龄17个月。

主要发现

  • 第二剂接种后30天内共观察到464例热性惊厥。
  • 调整潜在混杂因素后,MMRV对比MMR+V的热性惊厥OR为1.25(95%CI 0.67-2.30),MMRV对比MMR的OR为1.04(95%CI 0.82-1.32)。
  • 热性惊厥史是最重要的危险因素,OR为36.26(95%CI 29.30-44.89)。
  • 分层分析未发现年龄、性别、热性惊厥史或第一剂疫苗类型对风险存在效应修饰。

关键数值与推荐

  • 病例定义为因热性惊厥住院且无神经系统疾病编码为主要出院诊断。
  • 计算未调整和调整OR及95%CI以比较热性惊厥风险。

临床怎么用

  • 原文结论提示第二剂使用MMRV与MMR+V或MMR相比未增加热性惊厥风险,但原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Studies have shown an increased risk of febrile convulsions (FC) after first immunization with the quadrivalent measles-mumps-rubella-varicella vaccine (MMRV) compared to a first dose of measles-mumps-rubella vaccine (MMR) only or in combination with separately administered varicella vaccine (MMR + V). Therefore, it is recommended to give MMR + V at first dose and MMRV or MMR + V at second dose. Little is known on the risk of FC after MMRV at second dose, especially whether the risk depends on age, sex, history of FC or type of first dose vaccine. METHODS: A retrospective cohort study using claims data from the German Pharmacoepidemiological Research database (GePaRD) was performed in children born between January 1st, 2004 and October 31st, 2015 who received two doses of MMRV, MMR + V or MMR. Cases were defined as hospitalization with a diagnosis of FC without neurological conditions coded as main discharge diagnosis. Unadjusted and adjusted odds ratios (OR) with 95% confidence intevals (CIs) were calculated to compare the risk of FC. Stratified analyses were performed to examine potential effect modification by age, sex, history of FC or type of first dose vaccine. RESULTS: In the first 30 days after second dose vaccination, 464 FCs were observed in a cohort of 528,639 children with a median age of 17 months. After adjustment for potential confounders, the adjusted OR for FC in the 30 days after vaccination was 1.25 (95% CI 0.67-2.30) for MMRV compared to MMR + V and 1.04 (0.82-1.32) for MMRV compared to MMR. History of FC was the most important risk factor with an OR of 36.26 (29.30-44.89). We found no effect modification by age, sex, history of FC, or type of first dose vaccine. CONCLUSION: Use of MMRV at second dose is not associated with an increased risk of FC compared to MMR + V or MMR, irrespective of age, sex, history of FC, or type of first dose vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Schäfer W, Reinders T, Schink T, et al. Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions. Vaccine. 2022. PMID: 35232594. doi:10.1016/j.vaccine.2022.02.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。